RANI - NASDAQ
Rani Therapeutics Holdings, Inc.
$0.88
+2.9%Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
At a Glance
Live SnapshotRani Therapeutics Holdings, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Rani Therapeutics Holdings, Inc. Balance Sheet
RANI • NASDAQ
| Rani Therapeutics Holdings, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
ASSETS | |||||||
CURRENT ASSETS | |||||||
18.6M | 3.8M | 5.9M | 27M | 117.5M | 73.1M | 16.5M | |
31.1M | 23.9M | 42.7M | 71.5M | 0.0 | 0.0 | 0.0 | |
49.7M | 27.6M | 48.5M | 98.5M | 117.5M | 73.1M | 16.5M | |
2M | 428K | 200K | 0.0 | 0.0 | 1.7M | 250K | |
2M | 428K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 200K | 0.0 | 0.0 | 1.7M | 250K | |
0.0 | 0.0 | 1.3M | 1.9M | 2.1M | 167K | 158K | |
1.6M | 1.7M | 800K | 500K | 0.0 | 0.0 | 0.0 | |
53.3M | 29.7M | 50.8M | 100.9M | 119.6M | 74.9M | 16.9M | |
NON-CURRENT ASSETS | |||||||
5.1M | 6.6M | 6.8M | 7.1M | 4.6M | 4.5M | 4.5M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.6M | |
246K | 246K | 246K | 0.0 | 0.0 | 0.0 | 0.0 | |
5.3M | 6.9M | 7.1M | 7.1M | 4.6M | 4.5M | 6.1M | |
58.6M | 36.6M | 57.9M | 108M | 124.2M | 79.4M | 23M | |
LIABILITIES | |||||||
CURRENT LIABILITIES | |||||||
309K | 1.4M | 648K | 1.5M | 1.1M | 682K | 2.1M | |
309K | 1.4M | 648K | 1.5M | 1.1M | 537K | 198K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 145K | 1.9M | |
0.0 | 1.8M | 313K | 1.8M | 1.4M | 462K | 594K | |
1.6M | 15M | 4.9M | 0.0 | 0.0 | 1.4M | 0.0 | |
0.0 | 1.5M | 718K | 1M | 0.0 | 0.0 | 0.0 | |
6.8M | 0.0 | 1.2M | 0.0 | 0.0 | 2.7M | 179K | |
3.9M | 283K | 202K | 591K | 126K | 88K | 601K | |
12.7M | 19.9M | 8M | 4.8M | 2.6M | 5.3M | 3.5M | |
NON-CURRENT LIABILITIES | |||||||
2.7M | 9.6M | 24.5M | 29.1M | 0.0 | 2.4M | 115.5M | |
1.7M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 185M | 655K | |
4.4M | 13.3M | 24.5M | 29.2M | 0.0 | 187.4M | 116.2M | |
0.0 | 5.1M | 718K | 1.1M | 0.0 | 0.0 | 0.0 | |
17.1M | 33.1M | 32.5M | 34M | 2.6M | 192.8M | 119.7M | |
SHAREHOLDERS' EQUITY | |||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 185K | 116.2K | |
11K | 5K | 5K | 5K | 5K | 664K | 664K | |
0.0 | 104.9M | 85.8M | 75.8M | 55.7M | 0.0 | 0.0 | |
-132.6M | -102.9M | -72.9M | -38.9M | -8.3M | -114M | -97.3M | |
0.0 | 5K | -12K | -73K | 0.0 | -849K | -780.2K | |
165.6M | 0.0 | 0.0 | 0.0 | 0.0 | 664K | 664K | |
33M | 2M | 12.9M | 36.9M | 47.4M | -113.3M | -96.6M | |
41.5M | 3.5M | 25.4M | 74M | 121.6M | -113.3M | -96.6M | |
8.5M | 1.5M | 12.6M | 37.1M | 74.2M | 0.0 | 0.0 | |
SUMMARY | |||||||
58.6M | 36.6M | 57.9M | 108M | 124.2M | 79.4M | 23M | |
31.1M | 23.9M | 42.7M | 71.5M | 0.0 | 0.0 | 1.6M | |
4.3M | 29.7M | 30.1M | 30.2M | 0.0 | 3.8M | 115.5M | |
-14.3M | 25.9M | 24.2M | 3.2M | -117.5M | -69.3M | 99M | |
72,992,780 | 72,992,780 | 72,992,780 | 72,992,780 | 72,992,780 | 72,992,780 | 72,992,780 |
SEC Filings
RANI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 29, 2026 | May 28, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 27, 2026 | May 26, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 15, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 15, 2026 | May 11, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 16, 2026 | May 28, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 26, 2026 | March 26, 2026 | 2026 | |
8-K 8-K 2025 N/A | January 02, 2026 | December 31, 2025 | 2025 | |
S-3 S-3 N/A | November 07, 2025 | November 07, 2025 | ||
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your RANI research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.